RESULTS	With a median follow-up of 7.9 months , based on the 546 patients at study termination , median OS was 7.8 months in the gemcitabine plus placebo arm ( n = 275 ) versus 6.5 months in the gemcitabine plus aflibercept arm ( n = 271 ) , which was not significant ( hazard ratio 1.165 , 95 % confidence interval ( CI ) 0.921-1 .473 , p = 0.2034 ) .\